ALLERGAN
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 20 Aug 2024)
What this means for you
Registered since 10 Apr 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 86983196
- Registration number
- 5443889
- Mark type
- Design + words
- Filed
- 12 Jun 2015
- Published for opposition
- 01 Mar 2016
- Registered
- 10 Apr 2018
- Attorney of record
- Cheryl A. Withycombe
Goods and services
- Class 005 — Pharmaceuticals: House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations
- Class 010 — Medical apparatus: House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders
Owner
- Allergan, Inc., North Chicago, IL, US
- Allergan, Inc., Irvine, CA, US
- Allergan, Inc., Irvine, CA, US
Prior registrations
Prosecution history
- 20 Aug 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 20 Aug 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 20 Aug 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 05 Feb 2024 — TEAS SECTION 8 & 15 RECEIVED
- 10 Apr 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 10 Apr 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Apr 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 10 Apr 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 10 Apr 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 10 Apr 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 10 Apr 2018 — REGISTERED-PRINCIPAL REGISTER
- 03 Mar 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 02 Mar 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Feb 2018 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Feb 2018 — CORRESPONDENCE RECEIVED IN LAW OFFICE